SCHEMBL1669189

SCHEMBL1669189

Cn1c(N2CCOCC2)nc(-c2nc(Cc3ccc(F)cc3)no2)c(OCc2ccccc2)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
HSD17B10 Q99714 5/20 0.40
CYP1A2 P05177 5/20 0.40
CASP1 P29466 3/20 0.40
CASP7 P55210 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
DPP4 P27487 1/20 0.38
USP2 O75604 4/20 0.38
HIF1A Q16665 2/20 0.38
GLA P06280 1/20 0.38
CYP2C19 P33261 1/20 0.38
TSHR P16473 3/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
DGAT1 O75907 1/20 0.38
SOAT1 P35610 1/20 0.38
CYP2C9 P11712 2/20 0.37
LMNA P02545 1/20 0.37
NMT1 P30419 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12225285 0.88 ALDH1A1 (0.36) ALDH1A1HSD17B10CYP1A2CASP1CASP7
SCHEMBL1669331 0.83 PLAT (0.39) ALDH1A1HSD17B10CYP1A2CASP1CASP7
SCHEMBL1669609 0.83 ALDH1A1 (0.42) ALDH1A1HSD17B10CYP1A2CASP1CASP7
SCHEMBL1669215 0.83 MCHR1 (0.42) ALDH1A1HSD17B10CYP1A2CASP1CASP7
SCHEMBL823616 0.83 SLC2A1 (0.38) ALDH1A1HSD17B10CYP1A2CASP1CASP7
SCHEMBL1671403 0.73 DPP4 (0.47) ALDH1A1HSD17B10CYP1A2MEN1KMT2A
SCHEMBL10101646 0.71 ENPP2 (0.37) ALDH1A1HSD17B10CYP1A2CASP1CASP7
SCHEMBL12225688 0.70 ADORA2B (0.37) ALDH1A1L3MBTL1MAPK1
SCHEMBL12225746 0.70 PLAT (0.39) KMT2ANMT1L3MBTL1
SCHEMBL6095402 0.69 ALDH1A1 (0.50) ALDH1A1HSD17B10MEN1KMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383639-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed
US-8383639-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed
EP-2488517-A1 HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2012-08-22 EP disclosed
US-20110245241-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-10-06 US disclosed
US-20110245241-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-10-06 US disclosed
WO-2011046873-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245241-A1 HIV Integrase Inhibitors DNTT, POLB, UNG ALDH1A1 539/4885HSD17B10 652/4885CYP1A2 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.